09:24 AM EDT, 08/06/2025 (MT Newswires) -- Upstream Bio ( UPB ) reported a Q2 net loss Wednesday of $0.74 per share, narrowing from a loss of $6.5 a year earlier.

The biotechnology company, which finalized an initial public offering in October, had approximately 53.8 million shares outstanding as of June 30, compared with 3 million shares outstanding a year earlier.

Three analysts polled by FactSet expected a loss of $0.61.

Collaboration revenue for the quarter ended June 30 was $937,000, up from $510,000 a year earlier.

The company said that as of June 30 it had cash, cash equivalents and short-term investments of $393.6 million, which is expected to fund operations through 2027.